Cipla receives warning letter from USFDA for Goa manufacturing facility
26th Feb 2020

Cipla has received a warning letter from the United States Food and Drug Administration (USFDA) for its Goa manufacturing facility. The USFDA had conducted inspection from September 16, 2019 to September 27, 2019.The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.